Functional Fluidics Is Presenting At The Foundation for Sickle Cell Disease Research, April 28-30, Fort Lauderdale, FL
Dr. Patrick Hines chaired an education session on biomarkers and surrogate endpoints at the Foundation for Sickle Cell Disease Research (FSCDR) meeting the weekend of April 28-30th in Fort Lauderdale, FL. In addition to Dr. Hines, the session featured speakers from Pfizer, Wayne State University, Harvard, and Global Blood Therapeutics. The focus of the session was: “Can Novel Biomarkers Clarify Sickle Cell Disease Status and Effects of Disease-Modifying Therapies? Current Challenges – Future Opportunities (http://sched.co/A8XP)
Below is a recording of our presentation during the event:
No other contract research company has more experience performing blood function assays to evaluate anti-adhesive therapies in Sickle Cell Disease than Functional Fluidics.
This short video describes the origins of the company, based on research in the Hines Lab at Wayne State University. We have developed a suite of assays that address the need for better ways to assess blood function, starting with the experience of Dr. Hines as a Pediatric ICU Physician at Detroit Medical Center.
Assays At A Glance
The following is a list of standardized assays that we offer. Please click on any description for more information.
Blood samples (whole or isolated cellular components) at baseline or following drug treatment (single dose or dose response) are subjected to physiologic flow across an adhesive substrate of interest. Adhered cells are quantified to generate an adhesion index (AI).
Blood samples (whole or isolated platelets) are pre-treated with a drug of interest, and then subjected to physiologic arterial flow across a substrate of interest. A series of photomicrographs of fluorescently labeled blood (see Figure 3) is analyzed to determine the kinetics of thrombosis formation (lag time, max rate of thrombosis, area under the curve, and maximum amplitude).
Blood samples (whole or isolated cellular components) at baseline or following drug treatment (single dose or dose response) are subjected to physiologic flow across an adhesive substrate of interest (usually selectins). Time-lapse images are acquired to measure cell rolling / sliding along the channel surface. Mean velocity for rolling objects and cell flux is measured to generate a dynamic adhesion index (dAI).
Blood cells are adhered to a substrate of interest (see Flow Adhesion), followed by introduction of anti-adhesive drug under flow. Remaining adherent cells are measured to generate a reverse adhesion index (rAI).
Adhered cells are fixed with 4% formalin and stained following an adhesion assay (FF-FA, FF-FAR, FF-FAA). Fluorescence microscopy is utilized to differentiate between and quantify specific cell populations.
Blood cells are adhered to a substrate of interest (see Flow Adhesion), followed by introduction of sequentially increased shear. Remaining adherent cells are quantified followed by a sequential increase in shear (5, 10, and 20 dyne/cm^2), to generate an avidity adhesion index (aAI).